Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates

Vaccine

Volumn 32, Issue 24, 2014, Pages 2896-2903

  Fraser, Christopher C ^a   Altreuter, David H ^a   Ilyinskii, Petr ^a   Pittet, Lynnelle ^a   LaMothe, Robert A ^a   Keegan, Mark ^a   Johnston, Lloyd ^a   Kishimoto, Takashi Kei ^a  

^a Selecta Biosciences   (United States)

Author keywords

Antibodies; Epitope; Memory T cell; Nanoparticle; Vaccine

Indexed keywords

CATHEPSIN; DIPHTHERIA TOXOID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 MEMORY RECALL PEPTIDE; NICOTINE VACCINE; PEPTIDE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; MACACA FASCICULARIS; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY;

ANTIBODIES; EPITOPE; MEMORY T CELL; NANOPARTICLE; VACCINE;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DIPHTHERIA TOXOID; EPITOPES; FEMALE; GENES, MHC CLASS II; HUMANS; IMMUNOLOGIC MEMORY; MACACA FASCICULARIS; MACACA MULATTA; MICE; MICE, INBRED BALB C; NANOPARTICLES; NICOTINE; PEPTIDES; TETANUS TOXOID; VACCINES, SYNTHETIC;

EID: 84899953855     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.024     Document Type: Article

References (48)

1. Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology: the immune system in health and disease 2001, Garland Science, New York. 5th ed.
2. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1(9):751-761.
3. Panina-Bordignon P., Tan A., Termijtelen A., Demotz S., Corradin G., Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989, 19(12):2237-2242.
4. Ho P.C., Mutch D.A., Winkel K.D., Saul A.J., Jones G.L., Doran T.J., et al. Identification of two promiscuous T cell epitopes from tetanus toxin. Eur J Immunol 1990, 20(3):477-483.
5. Raju R., Navaneetham D., Okita D., Diethelm-Okita B., McCormick D., Conti-Fine B.M. Epitopes for human CD4+ cells on diphtheria toxin: structural features of sequence segments forming epitopes recognized by most subjects. Eur J Immunol 1995, 25(12):3207-3214.
6. Diethelm-Okita B.M., Raju R., Okita D.K., Conti-Fine B.M. Epitope repertoire of human CD4+ T cells on tetanus toxin: identification of immunodominant sequence segments. J Infect Dis 1997, 175(2):382-391.
7. Diethelm-Okita B.M., Okita D.K., Banaszak L., Conti-Fine B.M. Universal epitopes for human CD4+ cells on tetanus and diphtheria toxins. J Infect Dis 2000, 181(3):1001-1009.
8. Demotz S., Lanzavecchia A., Eisel U., Niemann H., Widmann C., Corradin G. Delineation of several DR-restricted tetanus toxin T cell epitopes. J Immunol 1989, 142(2):394-402.
9. O'Sullivan D., Sidney J., Del Guercio M.F., Colón S.M., Sette A. Truncation analysis of several DR binding epitopes. J Immunol 1991, 146(4):1240-1246.
10. O'Sullivan D., Arrhenius T., Sidney J., Del Guercio M.F., Albertson M., Wall M., et al. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol 1991, 147(8):2663-2669.
11. James E.A., Bui J., Berger D., Huston L., Roti M., Kwok W.W. Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition. Int Immunol 2007, 19(11):1291-1301.
12. Valmori D., Pessi A., Bianchi E., Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 1992, 149(2):717-721.
13. Le Gal F.A., Prevost-Blondel A., Lengagne R., Bossus M., Farace F., Chaboissier A., et al. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 2002, 98(2):221-227.
14. Junco J.A., Peschke P., Zuna I., Ehemann V., Fuentes F., Bover E., et al. Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate. Vaccine 2007, 25(50):8460-8468.
15. Bover Fuentes E., Fuentes Aguilar F., Junco Barranco J., Zaldivar Merino I., Arteaga Moré N., Calzada Aguilera L., et al. Active component of a GnRH based vaccine binds to natural GnRH receptors in Dunning R3327-G cell line and human prostate carcinoma vesicles. J Exp Ther Oncol 2007, 6(4):279-284.
16. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20(9):2106-2112.
17. Mortara L., Gras-Masse H., Rommens C., Venet A., Guillet J.G., Bourgault-Villada I. Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol 1999, 73(5):4447-4451.
18. Vitiello A., Ishioka G., Grey H.M., Rose R., Farness P., LaFond R., et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995, 95(1):341-349.
19. Lévy Y., Gahéry-Ségard H., Durier C., Lascaux A.S., Goujard C., Meiffrédy V., et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005, 18(19(3)):279-286.
20. Lévy Y., Durier C., Lascaux A.S., Meiffrédy V., Gahéry-Ségard H., Goujard C., et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006, 20(3):405-413.
21. Goujard C., Marcellin F., Hendel-Chavez H., Burgard M., Meiffrédy V., Venet A., et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res Hum Retroviruses 2007, 23(9):1105-1113.
22. Mahapatro A., Singh D.K. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol 2011, 9:55-66.
23. De Temmerman M.L., Rejman J., Demeester J., Irvine D.J., Gander B., De Smedt S.C. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 2011, 16(13-14):569-582.
24. Wang P., Sidney J., Dow C., Mothé B., Sette A., Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol 2008, 4(4):e1000048.
25. Wang P., Sidney J., Kim Y., Sette A., Lund O., Nielsen M., et al. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010, 11:568-580.
26. Lützner N., Kalbacher H. Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate. J Biol Chem 2008, 283(52):36185-36194.
27. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
28. Rivino L., Messi M., Jarrossay D., Lanzavecchia A., Sallusto F., Geginat J. Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med 2004, 200(6):725-735.
29. Sallusto F., Lanzavecchia A. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 2009, 39(8):2076-2082.
30. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10(11):787-796.
31. Rojas J.M., Knight K., Wang L., Clark R.E. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21(11):2287-2295.
32. Weber J.S., Hua F.L., Spears L., Marty V., Kuniyoshi C., Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 1999, 22(5):431-440.
33. Kuball J., de Boer K., Wagner E., Wattad M., Antunes E., Weeratna R.D., et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother 2011, 60(2):161-171.
34. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26(2):215-223.
35. Wierecky J., Müller M.R., Wirths S., Halder-Oehler E., Dörfel D., Schmidt S.M., et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006, 66(11):5910-5918.
36. Chu C.S., Boyer J., Schullery D.S., Gimotty P.A., Gamerman V., Bender J., et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012, 61(5):629-641.
37. Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity 2010, 33(4):451-463.
38. McKinstry K.K., Strutt T.M., Swain S.L. The potential of CD4 T-cell memory. Immunology 2010, 130(1):1-9.
39. MacLeod M.K., Clambey E.T., Kappler J.W., Marrack P. CD4 memory T cells: what are they and what can they do?. Semin Immunol 2009, 21(2):53-61.
40. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(4):247-258.
41. MacLeod M.K., David A., McKee A.S., Crawford F., Kappler J.W., Marrack P. Memory CD4T cells that express CXCR5 provide accelerated help to B cells. J Immunol 2011, 186(5):2889-2896.
42. Herzenberg L.A., Tokuhisa T., Herzenberg L.A. .Carrier-priming leads to hapten-specific suppression. Nature 1980, 285(5767):664-667.
43. Herzenberg L.A., Tokuhisa T., Hayakawa K. Epitope-specific regulation. Annu Rev Immunol 1983, 1:609-632.
44. Schutze M.P., Leclerc C., Jolivet M., Audibert F., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985, 135(4):2319-2322.
45. Gupta S.C., Hengartner H., Zinkernagel R.M. Primary antibody responses to a well-defined and unique hapten are not enhanced by preimmunization with carrier: analysis in a viral model. Proc Natl Acad Sci U S A 1986, 83(8):2604-2608.
46. Jegerlehner A., Wiesel M., Dietmeier K., Zabel F., Gatto D., Saudan P., et al. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 2010, 28(33):5503-5512.
47. Leclerc C., Schutze M.P., Deriaud E., Przewlocki G. The in vivo elimination of CD4+ T cells prevents the induction but not the expression of carrier-induced epitopic suppression. J Immunol 1990, 145(5):1343-1349.
48. Sad S., Rao K., Arora R., Talwar G.P., Raghupathy R. Bypass of carrier-induced epitope-specific suppression using a T-helper epitope. Immunology 1992, 76(4):599-603.